wsadcp conference seattle, wa. 10/18/13 neuroscientific basis of addiction & recovery darryl s....
TRANSCRIPT
![Page 1: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/1.jpg)
WSADCP Conference
Seattle, Wa.
10/18/13
Neuroscientific
Basis of Addiction &
Recovery
Darryl S. Inaba,
PharmD., CATC -V,
CADCIII
![Page 2: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/2.jpg)
Neuroscience of Addiction & Recovery Continues
• 10:30 am Developments in Addiction Treatment
• 1:15 pm Roots of Addiction
• 2:45 pm Current Trends in Substance Abuse
3 Stops Remaining
![Page 3: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/3.jpg)
![Page 4: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/4.jpg)
Part II: Developments in Addiction Treatment 10:30am – 12:00pm with Break
12-1:15am
Screening, Assessment, Intervention & Treatment Resources
Darryl S. Inaba, PharmD., CATC V, CADC III Darryl S. Inaba, PharmD., CATC V, CADC III Director: Clinical and Behavioral Health Services - Addictions Recovery Center
Research and Education - CNS Productions, Inc. Medford, Oregon
NIDA: Components of Comprehensive Drug
Abuse Treatment
![Page 5: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/5.jpg)
![Page 6: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/6.jpg)
![Page 7: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/7.jpg)
© 2007, CNS Productions, Inc.
![Page 8: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/8.jpg)
![Page 9: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/9.jpg)
![Page 10: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/10.jpg)
Addiction still requires a self-diagnosis for
effective treatment to commence
![Page 11: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/11.jpg)
Addiction Treatment Challenges
A. Barthwell (ONDCP), UFDS, TEDS• Awareness Gap- 76% who meet diagnostic criteria claim to have no problems (Denial)
• Motivation Gap- Only 5% who recognize their addiction problem will seek treatment
• Success Gap- 2% of those wanting and seeking treatment are unable to access it within a year, but only 50% get treatment ~on demand
• Continuity Gap- Only 25%-31% who enter treatment will complete with a + discharge
• Outcome Gap- 50% completers will remain abstinence for at least one year
![Page 12: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/12.jpg)
Addition Pathology Quick Review of
Parts I & III of Series
![Page 13: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/13.jpg)
Addiction Pathway Brain Circuits &
Processes Reward/Reinforcement Reward/Reinforcement (Go)(Go) [I prefer [I prefer Survival/Reinforcement]Survival/Reinforcement]
Hyperactivity then Hyperactivity then Hypoactivity Hypoactivity ControlControl (Stop)(Stop)
Impaired, dysfunctional Impaired, dysfunctional or or
disconnection of Go and disconnection of Go and StopStopBill Cohen: Overactive go, Damaged Stop Bill Cohen: Overactive go, Damaged Stop & Lack of Communication between them& Lack of Communication between them
![Page 14: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/14.jpg)
Relapse Related Brain Circuits and Processes
Stay Stopped (Slip Decisions) Stay Stopped (Slip Decisions)
Emotional Memory (Cravings)Emotional Memory (Cravings)
Stress Hormone Cycle Stress Hormone Cycle (Hypersensitivity) (Hypersensitivity)
![Page 15: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/15.jpg)
Stop Switch
GoSwitch
![Page 16: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/16.jpg)
Control Circuitry = Stop Switch
•Orbital Prefrontal Cortex – Especially left ventral medial OFC
•Fasciculus Retroflexus (anterior)
•Lateral Habenula (posterior and mesocortex terminal)
![Page 17: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/17.jpg)
Diathesis-Stress Model of Addiction & Related
Disorders• HEREDITY – Type I• ENVIRONMENTAL – Type II
Stress (esp. Trauma) & Poor Nutrition• PSYCHOACTIVE DRUG TOXICITY –
Type IIINote: each phenotype has to have
elements of the others to be activated
![Page 18: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/18.jpg)
![Page 19: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/19.jpg)
Assessment & Treatment of Substance-Related and
Addictive Disorders
![Page 20: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/20.jpg)
ScreeningScreening• Last use of tobacco, alcohol, drug Last use of tobacco, alcohol, drug
(Are you interested in quitting?) (Are you interested in quitting?)
• Ever experimented with drugs?Ever experimented with drugs?
• CAGE-AID (CAGE)CAGE-AID (CAGE)
• Quantity & frequency of use?Quantity & frequency of use?
• Can you abstain from alcohol while Can you abstain from alcohol while using RX? using RX?
• S-BIRT (Screen, Brief Intervention, S-BIRT (Screen, Brief Intervention, Referral Treatment) = 68% decrease Referral Treatment) = 68% decrease illicit drug useillicit drug use
![Page 21: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/21.jpg)
Research-Validated SUD Diagnosis and Assessment
Tools• Addiction Severity Index (ASI)• Michigan Alcoholism Screening Test
(MAST)B-MAST, MAST/AD, M-SAPS, SMAST-G
• DSM-IV-Tr, DSM-V by May 2013• CAGE-AID• 4P-Plus• TWEAK• ASAM PPC-2R (Six Dimensions)• ASSIST & NM ASSIST
![Page 22: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/22.jpg)
TREATMENT CONTINUUM
Detoxification Initial Abstinence Long-term Abstinence Recovery ASAM 4 Levels of Treatment:
IV, III.8, III.4, III.2, II.5, II, I, 0.5, et al.
![Page 23: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/23.jpg)
![Page 24: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/24.jpg)
![Page 25: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/25.jpg)
![Page 26: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/26.jpg)
![Page 27: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/27.jpg)
![Page 28: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/28.jpg)
![Page 29: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/29.jpg)
Addiction is a “tug of war” between the older Meso Cortex Survival Brain and the modern
thinking Neo Cortex Brain
Fish 500 myaCambrian Explosion
Reptiles 300 mya
Amphibians 315 mya
Mammals 220 mya
Primates 65 myaHominids 5 mya
Earth 4.5 Billion Years, Life from 4 Billion Years
![Page 30: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/30.jpg)
PrefrontalCortex
Nucleus Accumbens
Arcuate Nucleus Ventral
TegmentalArea
Brain Reward Pathways
Dopamine
Opioid Peptides
Glutamate
Courtesy of Dr. John Hart, Portland, Oregon
![Page 31: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/31.jpg)
Limbic Area• Role: Drive Generation (SURVIVAL)• Intervention: Pharmacotherapy
Thus, Both the Unconscious & Conscious Brain Require
Treatment Courtesy of Dr. John HartPrefrontal Cortex
• Role: Executive Function• Intervention: Counseling
![Page 32: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/32.jpg)
Clinical Treatments Targeted for Cortical (conscious) processes of
Addiction
![Page 33: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/33.jpg)
Clinical Interventions: Evidenced-Based & >100 yrs of Practiced-
Based Interventions• National Registry of Evidence-Based Program and Practices: SAMHSA & State
• Cognitive Behavioral Therapies: Motivational Interview/Enhancement, DBT
• Levels of Change• Individual and/or Group Counseling
(process, therapy, education, topical, open)
• Manual Driven Curricula (e.g. Matrix)• Self-Help Groups (12-Steps, et. al.)
![Page 34: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/34.jpg)
Treatments Targeted for Sub Cortical (unconscious)
Processes of Addiction
Sub Cortical Brain Structures
i.e. ~400 vaccines, genetic therapy, pharmaco-genomics, and ~more medication treatments in developments than any other medical condition
![Page 35: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/35.jpg)
Detox: Development of Withdrawal Management
Assessment Tools• CIWA-Ar Clinical Institute Withdrawal Assessment of Alcohol-Revised
• COWS, Clinical Opiate Withdrawal Scale• ACSA, Amphetamine Cessation
Symptom Assessment Scale• BWAS, Benzodiazepine Withdrawal
Assessment Scale• WAT-1, Withdrawal Assessment Tool
![Page 36: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/36.jpg)
Initial Abstinence: Pharmacological Cue Extinction via naltrexone and
acamprosate
![Page 37: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/37.jpg)
Meds for Alcohol Treatment• disulfiram (Antabuse®)
• naltrexone: (ReVia® daily or Vivitrol® injected monthly)
• acamprosate (Campral®)
• chlordiazepoxide (Librium®) or Off-Label phenobarbital, other benzodiazepine for short-term detox
• Off-Label: clonidine (Catapres®), lofexidine (Britlofex®)
• Off-Label Anti-Seizure meds: topiramate (Topamax®), gabapentin (Neurontin®)
• Misc. Off-Label: ondansetron (Zofran®), fluazenil in -Prometa, baclofen (Lioresal®), nalmefene (Revex®, Selincro®)
![Page 38: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/38.jpg)
Meds for Nicotine Treatment
• varenicline (Chantix®)
• bupropion (Zyban®, Wellbutrin®)• Nicotine Replacement Therapies
(NRT): gum (Nicorette®), patch (OTC-Nicotrol®, Nicoderm CQ®; Rx-ProStep®, Habitrol®), spray, inhaler, and lozenge
• Off-Label: nortriptyline, clonidine
![Page 39: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/39.jpg)
Meds for Opioid Treatment• buprenorphine (Suboxone®)
• naltrexone (Revia®, Trexan®, & Vivitrol®)
• methadone• levo-alpha-acetyl-methadol (LAAM)• Off-Label: clonidine, lofexidine• Off-Label: Rapid Opioid Detoxification
(naloxone or naltrexone with midazolam, lorazepam, clonidine, anesthetics, et al.)
• Illicit in U.S.: Ibogaine
![Page 40: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/40.jpg)
Buprenorphine (Suboxone) Ceiling Effect
![Page 41: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/41.jpg)
![Page 42: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/42.jpg)
Jackson County Rx OD deaths Courtesy of Dr. Jim Shames
![Page 43: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/43.jpg)
Suboxone more Rxed than methadone
![Page 44: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/44.jpg)
Centers for Disease Control and Prevention
(CDC) 7/3/12Steep Rise in Methadone OD deaths in 2000s Peaked out in 2007 and now falling
Still, methadone currently accounts for almost 1/3 of U.S. Rx medication deaths
In 2011 methadone was only 2% of all pain prescriptions yet responsible for more than 30% of Rx pain medication deaths
![Page 45: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/45.jpg)
Meds for Stimulant Treatment
Note: None FDA Approved so all are Off-Label
• Antidepressants: SSRI, TCA, bupropion• MAOI-B: selegiline• Neuroleptics: resperidone, olanzapine• Sedatives: buspirone, lorazepam• Dopaminergic: bromocriptine,
amantadine• Anti-seizures: topiramate, carbamazepine• Amino Acids: tyrosine, phenylalanine• Misc.: naltrexone, disulfiram, modafinil,
ALKS-33
![Page 46: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/46.jpg)
Meds for Sedative-Hypnotics
Note: None FDA Approved so all are Off-Label
• Usually cross-dependent medication is used and slowly tapered to detox
• Anti-seizure medications: phenobarbital + phenytoin or carbamazepine or gabapentin
• flumazenil post detox to block cravings
• SSRI, TCA, or buspirone for anxiety and/or restlessness
![Page 47: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/47.jpg)
Preview: Challenges to Maintenance of Continued
Abstinence • Cognitive Impairment (30-80%)
• Endogenous Craving (Allostasis)
• Environmental Triggers or Cues
• Post Acute Withdrawal Symptoms (PAWS)
• Unaddressed Mental Health Treatment Needs
![Page 48: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/48.jpg)
Courtesy of Daniel Amen, M.D.
Marijuana Abuse
All Addictive Substances ultimately shut down brain cell activity
![Page 49: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/49.jpg)
Right Insula Right Inferior Parietal Lobule
Similar Findings: Bando, Kenneth et al. Similar Findings: Bando, Kenneth et al. Am. J. of Psychiatry, 168(2):183-192, 2011Am. J. of Psychiatry, 168(2):183-192, 2011
Right InsulaRight Insula Right InferiorRight Inferior
Parietal LobuleParietal Lobule
Right MiddleRight MiddleTemporal GyrusTemporal Gyrus
Left Cauate/Left Cauate/PutamenPutamen
Left CingulateLeft CingulateGyrusGyrus
Courtesy of Paulus, M.P.; Tapert, S.F.; Courtesy of Paulus, M.P.; Tapert, S.F.; and Schuckit, M.A. l NIDA, Archives of and Schuckit, M.A. l NIDA, Archives of General Psychiatry, 62(7), 2005General Psychiatry, 62(7), 2005
![Page 50: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/50.jpg)
Dopamine Depletion in Addiction = Endogenous Craving and Anhedonia
![Page 51: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/51.jpg)
Endogenous or Intrapersonal Craving
Triggers• Boredom• Fears• Anxiety or depression• Anger/resentments• Guilt and Shame• Others:
dishonesty, exhaustion, cocky, complacent, self-pity, overconfidence, impatience
![Page 52: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/52.jpg)
Any Negative Mood State can initiate a Craving
Reaction• HALT – Hungry, Angry,
Lonely, Tired
• RIID – Restless, Irritable, Isolated,
Discontent
• BAAD – Bored, Anxious, Angry, Depressed
![Page 53: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/53.jpg)
Environmental or Interpersonal Triggers and
Cues• Any Sensory Input to addiction memories: visual, odor, auditory, physical withdraw, etc. – PTSD?
• Thoughts of using or of withdrawal• Other Interpersonal factors:
relationship problems, social/vocational pressures, no support system, negative life events, untreated dual diagnoses
![Page 54: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/54.jpg)
![Page 55: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/55.jpg)
Relapse Prevention “tool kits”• Exercise, Personal Recovery Network, Journaling, Self-
Help Groups (i.e. 12-Steps), Prayer, Artistic Expression
• Also Emotional Freedom Techniques (EMDR, Brain spotting, Tapping, Elastic Snapping)
• Yoga Breathing, Somantics, Figure 8 pacing
• Mindfulness Meditation & other Grounding Interventions including acupuncture, gardening
• Consequence Reminders (family picture, car key)
• Paradoxical Interventions (i.e. vial with emptied Librium capsules; Copenhagen can; go ahead and use but first turn your shirt inside out/wash off & reapply make-up
• What ever it takes not to initiate any action to use!
![Page 56: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/56.jpg)
Post Acute Withdrawal Syndrome (PAWS) – episodic or
recurrent• Sleep Disturbances – insomnia, nightmares• Memory Problems – Short-term, learning
• Thought Problems – concentration, rigidity, repetitive thoughts/behaviors, abstract thinking & problem solving difficulties
• Anxiety, irritability, hypersensitivity to stress• Inappropriate emotional reactions, mood
swings
• Physical and coordination difficulties, fatigue • Syndrome persists for 3-6 months, sleep
problems maybe longer – can be up to 2 years
![Page 57: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/57.jpg)
PAWS Treatment
• Clinical: CBT “grounding exercises”
• acamprosate for alcohol PAWS
• carbamazepine (Tegratol)
• Trazodone
• naltrexone
![Page 58: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/58.jpg)
Co-Occurring Disorder, Dual Diagnosis, MICA
• Prevalence depends on population studied• 44% alcohol abusers and 64.4% other
substance abusers met diagnoses for at least one major psychiatric disorder.
• 29% - 34% of those in mental health treatment met diagnostic criteria for an addiction and related disorder. Regier et al., 1990; Merikangas, Stevens, & Fenton, 1996
• Recovery difficult if MH disorders are not addressed
![Page 59: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/59.jpg)
RECOVERY The Resilient
Brain8-10 Months Rigorous Uninterrupted Treatment for Reasonable
OutcomesImplies time needed for brain to
become functionalTakes up to 2 years for greater
functioning to return
![Page 60: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/60.jpg)
Courtesy of Nora Volkow (Volkow, Hitzmann, Wong, et al 1992
![Page 61: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/61.jpg)
Courtesy of Nora Volkow, et al. Journal of Neuroscience, 21, 9414-9418, 2001
![Page 62: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/62.jpg)
Dopamine Transporter Binding (DAT) Recovery in
Meth Addiction
Volkow et al. J. of Neuroscience 2001
![Page 63: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/63.jpg)
Brain Recovery even after 7 years Methadone
and Xanax Exposure
![Page 64: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/64.jpg)
Dr. Ken Blum’s patented: Synapta GenX, KB220Z
Neuronutrient complex “normalization” of caudate, accumbens and putumen regions of heroin addicts demonstrated by fMRI Scan
![Page 65: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/65.jpg)
NIDA’s 13 Principles of Effective Treatment: A Research-Based Guide
![Page 66: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/66.jpg)
• Complex but treatable disease affecting brain function and behavior +/-
• No single treatment is appropriate for all +• Must be readily available -• Attends to the multiple needs of individuals
~ • Crucial to remain in treatment for adequate
period of time -• Individual, group and other evidence-based
behavioral therapies should be employed +• Medications combined with counseling and
behavioral therapies are important -
![Page 67: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/67.jpg)
• Service plans and treatment to be assessed continually and modified as needed +
• Evaluate & address mental health and other co-occurring disorders for best outcomes -
• Medically assisted detox is only a first step and has little impact on long-term outcomes -
• Treatment does not need to be voluntary to be effective + (by default)
• Rigorous monitoring throughout treatment for drug use may help reduce relapses -
• Disease assessment (i.e. HIV, HCV, HBV, TB) and Risk-Reduction Education a must ~+
![Page 68: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/68.jpg)
Elements of Successful Addiction Treatment
ProgramsHuman Intervention Motivation Study (HIMS) of American Airlines and United Airlines Impaired Pilots Treatment Programs Document 87%-95% Success
Impaired Physician Treatment Programs (i.e. University of Florida) enjoy 80%-90% Success
[‘Recovery Capital’ may be the major factor]
![Page 69: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/69.jpg)
10 Elements of Successful Addiction Treatment
ProgramsDr. Kevin T. McCauley @ CAADE 4/15/111) Start with Minimum 90 day Residential
Treatment2) Transition to Immediate Aftercare Program3) Ensure Sober-Living Environment Continuum
(Recovery Oriented System of Care)4) Mandated 90/90 Contract = 90 12-Step
Meetings in 90 days5) Automatic Plan Established for Any Slips with
goal of making each a learning opportunity
![Page 70: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/70.jpg)
10 Elements of Successful Addiction Treatment
ProgramsContinued6) Increased Drug Testing, both UA and
breathalyzer daily, even use of remote continual alcohol meter
7) Determine Rapid or Gradual Return to Duty8) Addictionologist a Must! Monitors Treatment
Intensely also a professional case manager9) Psychoactive Medication Only Via
Established Protocols10)Established “Fun in Recovery” Activities
![Page 71: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/71.jpg)
Recovery• Continued Abstinence
• Discovery of Natural Highs
• Recovery of neurotransmitters andof natural brain functions
• Positive lifestyles and quality of life enhancements
• Remember: Not an Event but a Process
One does not cure addiction, you treat it and manage it like any other chronic persistent medical disorder
![Page 72: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/72.jpg)
Treatment Works!Treatment Works!Treatment Works!Treatment Works!• 3 to 5 Yrs. Continued sobriety = 50% (1yr
80%)• Decrease Crime = 75%• $7-$12 Savings for every $1 Spent • Positive results from 6-8 mo. Treatment• Coerced treatment better than voluntary• Decreased Psychiatric (40%),
Family/Social (50-60%), Medical (15-20%), Employment Problems (15-20%)
• Culturally consistent better than generic treatments Belenko, et al. 2005
![Page 73: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/73.jpg)
•Good News! Recovery Works and the brain is resilient!
•Not so Good NewsIt takes time, several months to years to just become functional, and a bit more to enjoy life again
•Memory Protrusions Shrink with Disuse and new alternate pathways become established (“Extinction”) but addicted neurons are permanent and Recovery is a Life-Long Process!
![Page 74: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/74.jpg)
Conclusions◆ Addiction treatment results in miraculous outcomes for those who commit to and maintain continuous recovery efforts.
◆ Developments in treatments of addiction continues to improve outcomes that improve lives and health for all.
Me at Series End
![Page 75: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/75.jpg)
Thank You!
Darryl Inaba,
PharmD., CATC V,
CADC III
Disclosures:
Dominion Diagnostics
North Kingstown, RI;
CNS Productions
Medford, OR; J. of
Psychoactive Drugs,
San Francisco, CA
![Page 76: WSADCP Conference Seattle, Wa. 10/18/13 Neuroscientific Basis of Addiction & Recovery Darryl S. Inaba, PharmD., CATC -V, CADCIII](https://reader036.vdocuments.site/reader036/viewer/2022062714/56649cff5503460f949d04b8/html5/thumbnails/76.jpg)
Lunch Break: Reality Bites!
Fantasy Reality!Vs.